Tekmira STILL Getting Love on Ebola Hype
Insights - In which we suggest taking profit and/or selling Calls on TKMR equity position. A handy return from $11.50 in July.
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
MannKind Lands a Partner, Bull/Bear Debate Continues
Research - Drug developer (and battleground biotechnology stock) Mannkind Corp (MNKD) has partnered with Sanofi (SNY) for the global commercialization of its approved inhaled insulin product, Afrezza. MNKD jumped 20% on … Continue Reading
Read now
It Seems the Ebola Trade is Still On After All
Recap - BOOM! Shares of Tekmira Pharmaceuticals (TKMR) climbed from $14 to $20 into Friday’s close after the FDA removed a clinical hold on the company’s Ebola therapeutic, essentially enabling its … Continue Reading
Read now
Coming Up: Make or Break for Amicus’ Pharmacological Chaperone Technology
Research - Amicus Therapeutics (FOLD), with a current market value of just $271 million, represents a high-risk, high reward play for investors willing to bet that the … Continue Reading
Premium
Takeaways from Orexigen’s Second Quarter Conference Call
Research - Orexigen Therapeutics (OREX) on Thursday reported second quarter results. We’re bullish on OREX in the near-term, but some revelations on the company’s conference call work against the … Continue Reading
Read nowARIAD Misses Wall Street Expectations
Insights - Investors and analysts expected more out of Ariad Pharmaceuticals’ (ARIA) Iclusig in the second quarter and punished the stock when sales from the company’s only … Continue Reading
Read now
Regeneron Slips in Pre-Market after Strong Sales Report
Insights - Despite encouraging quarterly U.S. sales from its Eylea treatment for macular degeneration, reported on Tuesday morning, Regeneron Pharmaceuticals’ (REGN) shares were down more than two … Continue Reading
Read now